GlassScriptPhysician profile
Wilfredo A Munoz
NPI 1194898395
$2,380.90
in general payments reported to CMS, 2019-2025
30 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $441 · 2021: $383 · 2022: $217 · 2023: $335 · 2024: $155 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $218.44 | 2019-2025 | |
| Abbott Laboratories | $181.55 | 2025 | Jot Dx |
| Lilly USA, LLC | $180.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $171.68 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $166.14 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $156.65 | 2019-2020 | |
| Abbvie INC. | $145.34 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $140.48 | 2019-2022 | |
| Horizon Therapeutics Plc | $129.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.74 | 2019-2024 | Farxiga, Breztri |
| Amarin Pharma, INC. | $86.55 | 2020-2021 | |
| Radius Health, INC. | $85.90 | 2019-2020 | |
| Astellas Pharma US INC | $78.85 | 2020-2024 | Veozah |
| Redhill Biopharma INC. | $77.46 | 2020-2021 | |
| Biogen, INC. | $72.10 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.05 | 2019-2025 | Xifaxan |
| Smith+Nephew, INC. | $45.24 | 2019-2021 | |
| Dexcom, INC. | $33.60 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $28.51 | 2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $26.96 | 2021-2022 | |
| Eisai INC. | $25.52 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.94 | 2024 | |
| Phathom Pharmaceuticals, INC. | $22.55 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $21.82 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.74 | 2022 | |
| Amgen INC. | $19.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.95 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.79 | 2024 | |
| Pfizer INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfredo Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.